story of the week
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Patients With Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
JAMA Oncol 2020 Jul 16;[EPub Ahead of Print], I Puzanov, A Ribas, C Robert, J Schachter, M Nyakas, A Daud, A Arance, MS Carlino, SJ O'Day, GV Long, KA Margolin, R Dummer, D Schadendorf, J Lutzky, PA Ascierto, A Tarhini, J Lin, R Mogg, B Homet Moreno, N Ibrahim, O HamidFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.